Theravance Biopharma, Inc. Stock price

Equities

TBPH

KYG8807B1068

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
8.97 USD -0.44% Intraday chart for Theravance Biopharma, Inc. +0.11% -20.20%
Sales 2024 * 73M Sales 2025 * 97.03M Capitalization 432M
Net income 2024 * -31M Net income 2025 * -16M EV / Sales 2024 * 5.92 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.45 x
P/E ratio 2024 *
-13.9 x
P/E ratio 2025 *
-27.5 x
Employees 99
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.84%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.44%
1 week+0.11%
Current month-5.28%
1 month-4.57%
3 months-20.69%
6 months+7.04%
Current year-20.20%
More quotes
1 week
8.65
Extreme 8.65
9.09
1 month
8.42
Extreme 8.42
9.65
Current year
8.21
Extreme 8.21
11.71
1 year
8.21
Extreme 8.21
12.03
3 years
6.10
Extreme 6.1
22.74
5 years
6.10
Extreme 6.1
31.54
10 years
6.10
Extreme 6.1
43.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 13-06-30
Director of Finance/CFO 42 14-05-31
Chief Tech/Sci/R&D Officer - 14-10-31
Members of the board TitleAgeSince
Director/Board Member 68 14-05-31
Director/Board Member 65 14-06-01
Director/Board Member 90 13-09-30
More insiders
Date Price Change Volume
24-03-28 8.97 -0.44% 401,710
24-03-27 9.01 +2.15% 320,008
24-03-26 8.82 +0.68% 296,175
24-03-25 8.76 -1.79% 365,382
24-03-22 8.92 -0.45% 303,569

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
8.97 USD
Average target price
14 USD
Spread / Average Target
+56.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Theravance Biopharma, Inc. - Nasdaq